The estimated Net Worth of Frank Karbe is at least $10.3 Millón dollars as of 7 July 2021. Mr. Karbe owns over 3,232 units of Myovant Sciences Ltd stock worth over $5,727,746 and over the last 21 years he sold MYOV stock worth over $583,067. In addition, he makes $4,021,290 as Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences y Inc. at Myovant Sciences Ltd.
Frank has made over 30 trades of the Myovant Sciences Ltd stock since 2008, according to the Form 4 filled with the SEC. Most recently he sold 3,232 units of MYOV stock worth $70,296 on 7 July 2021.
The largest trade he's ever made was exercising 24,800 units of Myovant Sciences Ltd stock on 28 August 2020 worth over $126,728. On average, Frank trades about 2,478 units every 76 days since 2004. As of 7 July 2021 he still owns at least 212,296 units of Myovant Sciences Ltd stock.
You can see the complete history of Mr. Karbe stock trades at the bottom of the page.
Frank L. Karbe serves as Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc. of the Company. of the Company. of the Company. of the Company. of the Company. of the Company. of the Company. Mr. Karbe has served as our Principal Financial and Accounting Officer since September 2016. Mr. Karbe was appointed as Myovant Sciences, Inc.’s Chief Financial Officer in April 2017 and was subsequently appointed as President and Chief Financial Officer in February 2020. From September 2014 to July 2016, Mr. Karbe served as President of The Color Run, a global mass participation events platform, where he was responsible for leading the operational and financial functions. From January 2004 to June 2014, Mr. Karbe was the Executive Vice President and Chief Financial Officer of Exelixis, Inc., a biotechnology company. During his tenure at Exelixis, Mr. Karbe was responsible for leading the finance organization, internal and external communications, business development, information technology, corporate strategy and various other operational functions. Prior to joining Exelixis in 2004, Mr. Karbe worked as an investment banker for Goldman Sachs & Co., where he served most recently as Vice President in the healthcare group advising clients on corporate finance and mergers and acquisitions. Prior to joining Goldman Sachs in 1997, Mr. Karbe held various positions in the finance department of The Royal Dutch/Shell Group in Europe. Mr. Karbe has served as a director of Aduro Biotech, Inc. since April 2019. Mr. Karbe also served as a director of Arbutus Biopharma Corporation from 2010 to 2018. Mr. Karbe received his Diplom-Kaufmann from the WHU-Otto Beisheim Graduate School of Management, Koblenz, Germany.
As the Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences y Inc. of Myovant Sciences Ltd, the total compensation of Frank Karbe at Myovant Sciences Ltd is $4,021,290. There are 2 executives at Myovant Sciences Ltd getting paid more, with Lynn Seely having the highest compensation of $6,222,670.
Frank Karbe is 52, he's been the Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences y Inc. of Myovant Sciences Ltd since 2020. There are 8 older and 5 younger executives at Myovant Sciences Ltd. The oldest executive at Myovant Sciences Ltd is Kathleen Sebelius, 72, who is the Lead Independent Director.
Frank's mailing address filed with the SEC is C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK, NJ, 07932.
Over the last 8 years, insiders at Myovant Sciences Ltd have traded over $5,780,890 worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth $2,001,605,371 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... y Andrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $25,106,967. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth $1,393,178,400.
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
Myovant Sciences Ltd executives and other stock owners filed with the SEC include: